Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

Abstract

This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.

Keywords:

• Diffuse large B-cell lymphoma
• allogeneic hematopoietic stem cell transplant
• economic burden
• healthcare resource utilization
• healthcare costs

Acknowledgments

Financial support for this study was provided by Novartis Pharmaceuticals Corporation. The authors thank Cinzia Metallo, PhD, an employee of Analysis Group Inc., for editorial assistance, funded by Novartis Pharmaceuticals Corporation.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http:\\10.1080/10428194.2017.1375100.

Additional information

Funding

This work was funded by Novartis Pharmaceuticals Corporation. Richard T. Maziarz is an employee of Oregon Health & Science University who provided and received payment for consultant services to Novartis Pharmaceuticals Corporation. This potential conflict of interest has been reviewed and managed by OHSU. Yanni Hao, Simu K Thomas, and Lamis Eldjerou are employees of Novartis Pharmaceuticals Corporation, which provided funding for this research. Annie Guerin, Genevieve Gauthier, and Marjolaine Gauthier-Loiselle are employees of Analysis Group Inc., which received consultancy fees from Novartis Pharmaceuticals Corporation for this research.